<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01796418</url>
  </required_header>
  <id_info>
    <org_study_id>BESTinDN-001</org_study_id>
    <nct_id>NCT01796418</nct_id>
  </id_info>
  <brief_title>Beraprost Sodium and Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy</brief_title>
  <official_title>Effect of Beraprost Sodium on Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy (BESTinDN Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Korea, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic nephropathy, the leading cause of end-stage renal disease in many countries, is
      characterized by high cardiovascular mortality and morbidity even in the early course of the
      disease. In addition, cardiovascular complication has been the most common cause of death in
      these patients. Thus, early detection and appropriate intervention for this highly common and
      critical complication is considered to play an important role in the management of the
      disease. In this regard, much interest has been focused on the early markers which can
      predict arterial diseases before the clinically apparent cardiovascular diseases. Recently,
      glowing evidence suggests that arterial stiffness as assessed by pulse wave velocity (PWV)
      may serve as a surrogate marker for future cardiovascular disease. In fact, increased PWV has
      been known to be independently associated with diabetic nephropathy in type 2 diabetes.

      Beraprost sodium (BPS) is a stable orally active prostacyclin (PGI2) analogue that has a
      potent vasodilatory and anti-platelet effect. Also, BPS has been suggested to improve a
      micro-vascular circulation through a reduction of red blood cell deformability. In addition,
      recent studies have demonstrated that BPS improves endothelial function through an increase
      in endothelial nitric oxide synthesis and NO synthase gene transcription. These beneficial
      effects of BPS have been known to reduce PWV in patients prone to cardiovascular diseases
      such as elderly, hypertension, or a history of cerebral infarction. However, the effect of
      BPS on arterial stiffness in patients with diabetic nephropathy remains elusive. Our study
      will address the effect of BPS on arterial stiffness by PWV in patients with diabetic
      nephropathy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brachial ankle pulse wave velocity (PWV)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The change of brachial ankle PWV at 12 weeks compared to baseline (0 week)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ankle brachial indices (ABI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The change of ABI at 12 weeks compared to baseline (0 week)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine albumin creatinine ratio (UACR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The change of UACR at 12 weeks compared to baseline (0 week)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IDMS MDRD estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The change of IDMS MDRD eGFR at 12 weeks compared to baseline (0 week)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profiles</measure>
    <time_frame>12 weeks</time_frame>
    <description>The change of total cholesterol, LDL-cholesterol, and triglyceride at 12 weeks compared to baseline (0 week)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>The change of systolic and diastolic blood pressure at 12 weeks compared to baseline (0 week)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Beraprost sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beraprost sodium 0.02 mg capsule by mouth every 12 hours for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule by mouth every 12 hours for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beraprost sodium</intervention_name>
    <arm_group_label>Beraprost sodium</arm_group_label>
    <other_name>Berasil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 19 years or more and 75 years or less

          -  Type 2 diabetes who is prescribed glucose-lowering agent or insulin

          -  Estimated glomerular filtration rate (GFR) by isotope dilution mass spectrometry
             (IDMS)- Modification of Diet in Renal Disease (MDRD) equation 30 ml/min/1.73 m2 or
             more

          -  verified 2 times or more of albuminuria 30 mg/g cr (or protein 300 mg/g cr)or more in
             a spot urine sample with interval of 1 week or more in recent 6 months

          -  Patients whose blood pressure is 140/90 mmHg or less and did not receive a
             prescription for additional antihypertensive medication in recent 3 months

          -  Patients who give written consent to this study by oneself

        Exclusion Criteria:

          -  History of kidney transplantation

          -  current advanced congestive heart failure (NYHA class III or more)

          -  current uncontrolled arrhythmia

          -  current advanced liver cirrhosis (Child-Pugh class C)

          -  History of bleeding diathesis

          -  current active infection or uncontrolled inflammatory disorders

          -  History of cerebrovascular accident or myocardial infarction

          -  current use of anticoagulant

          -  current use of two or more antiplatelet agents

          -  patients with advanced malignancy (life expectancy less than 6 months)

          -  patients with uncontrolled diabetes (Hba1c more than 10%)

          -  patients with severe anemia (Hb less than 8.0 g/dL)

          -  female who are pregnant, trying to get pregnant or lactating

          -  Genetic diseases such as galactose intolerance, lactose deficiency or
             glucose-galactose malabsorption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chun-Soo Lim, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong Ki Kim, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ki Young Na, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sung Gyun Kim, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young-Ki Lee, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Kangnam Sacred Heart Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chun-Soo Lim, Prof</last_name>
    <phone>82-2-870-2120</phone>
    <email>cslimjy@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dong Ki Kim, Prof</last_name>
    <phone>82-2-2072-2303</phone>
    <email>dkkim73@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Gyun Kim, Prof</last_name>
      <phone>82-31-380-3728</phone>
      <email>sgkim@hallym.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Sung Gyun Kim, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki Young Na, Prof</last_name>
      <email>kyna@snubh.org</email>
    </contact>
    <investigator>
      <last_name>Ki Young Na, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kangnam Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Ki Lee, Prof</last_name>
      <phone>82-2-829-5114</phone>
      <email>km2071@naver.com</email>
    </contact>
    <investigator>
      <last_name>Young-Ki Lee, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun-Soo Lim, Prof</last_name>
      <phone>82-2-872-2120</phone>
      <email>cslimjy@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Chun-Soo Lim, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Ki Kim, Prof</last_name>
      <phone>82-2-2072-2303</phone>
      <email>dkkim73@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dong Ki Kim, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007 Jul 3;116(1):85-97. Review.</citation>
    <PMID>17606856</PMID>
  </reference>
  <reference>
    <citation>Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005 Feb;16(2):489-95. Epub 2004 Dec 8.</citation>
    <PMID>15590763</PMID>
  </reference>
  <reference>
    <citation>Melian EB, Goa KL. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs. 2002;62(1):107-33. Review.</citation>
    <PMID>11790158</PMID>
  </reference>
  <reference>
    <citation>Sugawara A, Kudo M, Saito A, Matsuda K, Uruno A, Ito S. Novel effects of beraprost sodium on vasculatures. Int Angiol. 2010 Apr;29(2 Suppl):28-32. Review.</citation>
    <PMID>20357746</PMID>
  </reference>
  <reference>
    <citation>Goya K, Otsuki M, Xu X, Kasayama S. Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus. Metabolism. 2003 Feb;52(2):192-8.</citation>
    <PMID>12601631</PMID>
  </reference>
  <reference>
    <citation>Nakayama T, Hironaga T, Ishima H, Maruyama T, Masubuchi Y, Kokubun S. The prostacyclin analogue beraprost sodium prevents development of arterial stiffness in elderly patients with cerebral infarction. Prostaglandins Leukot Essent Fatty Acids. 2004 Jun;70(6):491-4.</citation>
    <PMID>15120711</PMID>
  </reference>
  <reference>
    <citation>Nakayama T, Masubuchi Y, Kawauchi K, Masaki R, Hironaga T, Ishima H, Torigoe M, Shimabukuro H. Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction. Prostaglandins Leukot Essent Fatty Acids. 2007 Jun;76(6):309-14. Epub 2007 Jul 9.</citation>
    <PMID>17616452</PMID>
  </reference>
  <reference>
    <citation>Watanabe M, Nakashima H, Ito K, Miyake K, Saito T. Improvement of dyslipidemia in OLETF rats by the prostaglandin I(2) analog beraprost sodium. Prostaglandins Other Lipid Mediat. 2010 Sep;93(1-2):14-9. doi: 10.1016/j.prostaglandins.2010.04.003. Epub 2010 May 5.</citation>
    <PMID>20450981</PMID>
  </reference>
  <reference>
    <citation>Sato N, Kaneko M, Tamura M, Kurumatani H. The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats. Diabetes. 2010 Apr;59(4):1092-100. doi: 10.2337/db09-1432. Epub 2010 Jan 12.</citation>
    <PMID>20068136</PMID>
  </reference>
  <reference>
    <citation>Rubin MF, Rosas SE, Chirinos JA, Townsend RR. Surrogate markers of cardiovascular disease in CKD: what's under the hood? Am J Kidney Dis. 2011 Mar;57(3):488-97. doi: 10.1053/j.ajkd.2010.08.030. Epub 2010 Dec 18. Review.</citation>
    <PMID>21168944</PMID>
  </reference>
  <reference>
    <citation>Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006 Aug 15;145(4):247-54. Erratum in: Ann Intern Med. 2008 Oct 7;149(7):519.</citation>
    <PMID>16908915</PMID>
  </reference>
  <reference>
    <citation>Noordzij M, Tripepi G, Dekker FW, Zoccali C, Tanck MW, Jager KJ. Sample size calculations: basic principles and common pitfalls. Nephrol Dial Transplant. 2010 May;25(5):1388-93. doi: 10.1093/ndt/gfp732. Epub 2010 Jan 12. Erratum in: Nephrol Dial Transplant. 2010 Oct;25(10):3461-2.</citation>
    <PMID>20067907</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2013</study_first_submitted>
  <study_first_submitted_qc>February 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2013</study_first_posted>
  <last_update_submitted>December 13, 2013</last_update_submitted>
  <last_update_submitted_qc>December 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Dong Ki Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beraprost</mesh_term>
    <mesh_term>Epoprostenol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

